



3708 Fifth Avenue
Medical Arts Building, Suite 503
Pittsburgh, PA 15213

Phone: 412-647-6111

www.aaci-cancer.org



OCTOBER 14-16

*CME sponsored jointly by the Vanderbilt School of Medicine
and the Association of American Cancer Institutes*

Table of Contents

Welcome	1
Program Committee	2
Agenda	3
Speakers	12
Awardee Profiles	31
Support	34
Exhibitors	35

Welcome

The cancer centers represented by the Association of American Cancer Institutes (AACI) form America’s cancer research infrastructure and are the hubs of critical discoveries, treatment advances and improvements in patient care. AACI and the Cancer Center Administrators Forum (CCAF) jointly formulated the program for the 2012 AACI/CCAF Annual Meeting.

This event convenes AACI cancer center directors and executive-level administrators with leaders of national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges and to share best practices. No other program presents information on cancer research and patient care issues as they pertain to the leaders of the nation’s cancer centers, and provides them with a forum to discuss common issues. The gathering also affords an opportunity to acknowledge scientific leaders and individuals in public service who help to advance and promote cancer research.

Meeting sessions will focus in part on the intersection of science and cancer center operations in the areas of prevention, screening, diagnostics and disparities.

Program Committee

2012 AACI/CCAF Annual Meeting Program Committee Members

Chair: Dan Theodorescu, MD, PhD
University of Colorado Cancer Center

Michelle M. Le Beau, PhD
University of Chicago Comprehensive Cancer Center

William S. Dalton, PhD, MD
Moffitt Cancer Center & M2Gen

David Rubenson
Stanford Cancer Institute

Chi Van Dang, MD, PhD
Abramson Cancer Center of the University of Pennsylvania

Brian C. Springer, MHA
Roswell Park Cancer Institute

Michael W. Darling, MHA
IU Simon Cancer Center
Indiana University

Barbara Duffy Stewart, MPH
Association of American Cancer Institutes

Peter D. Emanuel, MD
Winthrop P. Rockefeller Cancer Institute
University of Arkansas for Medical Sciences

Tim Strawderman
University of Texas Southwestern
Simmons Comprehensive Cancer Center

Gordon D. Ginder, MD
Massey Cancer Center
Virginia Commonwealth University

Donald L. Trump, MD, FACP
Roswell Park Cancer Institute

Dina Gould Halme, PhD
University of Virginia Cancer Center

Kristiina Vuori, MD, PhD
Sanford-Burnham Medical Research Institute

Mark Kochevar, MBA
University of Colorado Cancer Center
University of Colorado Health Sciences Center

Agenda

Sunday, October 14

11:00 am Registration Begins
Grand Court

12:00 pm Exhibits Open
Grand Court

1:00 pm Welcome and AACI Business Meeting

President's Report
Dr. William S. Dalton
Moffitt Cancer Center & M2Gen

Executive Director's Report
Ms. Barbara Duffy Stewart
Association of American Cancer Institutes

Treasurer's Report
Ms. Dorothy Puh
Dana-Farber Cancer Institute

Welcome
Dr. Dan Theodorescu
University of Colorado Cancer Center

CCAF Report
Mr. Brian Springer
Roswell Park Cancer Institute

1:45 pm Innovative and Affordable Health Care
Dr. Mark B. McClellan
Engelberg Center for Health Care Reform
The Brookings Institution

2:45 pm Break

All 2012 AACI/CCAF Annual Meeting sessions will be held in the Grand Ballroom, River II Level.

Agenda

Sunday, October 14 *continued*

3:00 pm **NCI Office of Cancer Centers Update**
Dr. Linda K. Weiss
National Cancer Institute

4:00 pm **CCAF Business Meeting** (open only to CCAF Members)

5:00 pm **Adjourn**

6:00 – 7:30 pm **Welcome Reception**
Grand Court

Monday, October 15

7:00 – 8:00 am **Breakfast**
Promenade Ballroom

7:00 am **Concurrent Roundtable Discussions – New CCSG Guidelines**
Promenade Ballroom

How to Prepare for One of the First Cycles of the New Guidelines
Ms. Mary Sumpmann
Masonic Cancer Center, University of Minnesota

Outsourcing or Sharing Shared Resources
Mr. Dale Henry
Roswell Park Cancer Institute

Addressing and Assessing Scientific Impact Including Comprehensiveness
Dr. Barbara Vance
Abramson Cancer Center of the University of Pennsylvania

Demonstrating Value of Science to the Catchment Area
Dr. Dina Gould Halme
University of Virginia Cancer Center

7:00 am **Exhibits Open**
Grand Court

Program Subject to Change

Monday, October 15 *continued*

8:00 am **How do Cancer Centers Handle Screening Amidst Conflicting Recommendations?**
Moderator: Dr. Shelton Earp
*UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill*

Breast and Prostate Cancer Screening Recommendations from the US Preventive Services Task Force—Balancing Benefits and Harms to Optimize Health Outcomes
Dr. Timothy Wilt
U.S. Preventive Services Task Force

Why PSA Testing Should be Done
Dr. William Catalona
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Prostate Cancer Screening: The Recommendations of Respected Medical Organizations
Dr. Otis W. Brawley
American Cancer Society

9:30 am **Break**

9:45 am **Balancing the Budget: The Role of Cancer Centers in Discovery and Validation of Companion Diagnostics**
Moderator: Ms. Lauren Hackett
Vanderbilt-Ingram Cancer Center

Enabling Genetically Informed Cancer Medicine in the Clinic
Dr. Mia Levy
Vanderbilt-Ingram Cancer Center

Identification and Validation of Predictive Markers for Oncology Therapeutic Development
Dr. Ian McCaffery
Genentech

The Challenges of Drug-Diagnostic Co-Development: A BioPharmaceutical Perspective
Dr. Steven D. Averbuch
Bristol-Myers Squibb

Program Subject to Change

Agenda

Monday, October 15 *continued*

11:15 am **AACI Translational Cancer Research Fellowship**

Fellowship Overview
Dr. Beverly S. Mitchell
Stanford Cancer Institute

Introduction

Dr. Frederick R. Appelbaum
Fred Hutchinson Cancer Research Center

Defining Glioma Neural Stem Cell Self-Renewal Networks

Dr. Yu Ding
Fred Hutchinson Cancer Research Center

11:45 am **AACI Awards Luncheon**

Promenade Ballroom

2012 AACI Distinguished Public Service Award

Sen. Jerry Moran (R-KS)

2012 AACI Distinguished Public Service Award

Rep. Debbie Wasserman Schultz (D-FL)

AACI Special Recognition Award

Dr. Alan S. Rabson (award accepted by Dr. Arnold B. Rabson)
National Cancer Institute

2012 AACI Distinguished Scientist Award

Dr. Margaret Spitz
The Dan L. Duncan Cancer Center at Baylor College of Medicine

1:45 pm **2012 AACI Distinguished Scientist Keynote Address**

Integrative Epidemiology: Next Generation

Dr. Margaret Spitz

2:45 pm **AACI Clinical Research Initiative Update**

Dr. Tony Reid
Moore's UCSD Cancer Center

Ms. Janie Hofacker
Association of American Cancer Institutes

3:15 pm **Break**

Monday, October 15 *continued*

3:30 pm **Integrating Prevention and Control with Basic and Clinical Research: Experiences at Selected Centers**

Moderator: Dr. Tom Sellers
Moffitt Cancer Center

Dr. Caryn Lerman

Abramson Cancer Center, University of Pennsylvania

Dr. Stephen B. Gruber

USC Norris Comprehensive Cancer Center

Dr. Marcy List

University of Chicago Cancer Research Center

5:00 pm **Adjourn**

Tuesday, October 16

7:00 – **Breakfast**

8:00 am
Promenade Ballroom

7:00 am **Concurrent Roundtable Discussions – New CCSG Guidelines**

Promenade Ballroom

How to Prepare for one of the First Cycles of the New Guidelines

Mr. Rob DuWors

Jonsson Comprehensive Cancer Center, UCLA

Outsourcing or Sharing Shared Resources

Mr. Bob Gerlach

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center

Addressing and Assessing Scientific Impact Including Comprehensiveness

Mr. Michael Vander Hoek

Lombardi Comprehensive Cancer Center at Georgetown University

Demonstrating Value of Science to the Catchment Area

Dr. Dina Gould Halme

University of Virginia Cancer Center

Agenda

Tuesday, October 16 *continued*

7:00 am Exhibits Open

Grand Court

8:00 am Obesity, Energetics and Cancer: Policy and Implementation

Together We Must Stamp Out the Obesity Epidemic

Moderator: Dr. David S. Alberts

University of Arizona Cancer Center

Diet, Lifestyle and Cancer: What Do We Know?

Dr. Walter Willett

Harvard University

Opportunities for Collaboration between Cancer Centers and Communities: CDC's Chronic Disease Prevention Programs

Dr. Pamela Protzel Berman

*Division of Cancer Prevention and Control
Centers for Disease Control and Prevention*

Advocacy and Policy Issues Related to Community-level Health Promotion Activities

Dr. Alan Balch

Preventive Health Partnership

Biological Mechanisms and Obesity-Associated Cancers: Opportunities for Intervention

Dr. Patricia Thompson

University of Arizona Cancer Center

9:30 am Break

9:45 am NCI Director's Office Update

Dr. Douglas R. Lowy

National Cancer Institute

Tuesday, October 16 *continued*

10:45 am The Economics of Addressing Disparities at Cancer Centers

Maximizing the Cost Effectiveness of Cancer Screening Navigation Programs

Dr. Carmen Guerra

*Abramson Cancer Center
University of Pennsylvania*

Research in Disparities at Cancer Centers — Programmatic and Economic Issues

Dr. Alfred I. Neugut

*Herbert Irving Comprehensive Cancer Center
Columbia University*

Driving It Home: The Economics of Taking Mammography Services on the Road to Benefit UAMS and Arkansas Women

Ms. Shirley W. Gray

*The Winthrop P. Rockefeller Cancer Institute
University of Arkansas for Medical Sciences*

Research and Service: Strange Bedfellows or Match Made In Heaven?

Moderator: Dr. Edward E. Partridge

*University of Alabama at Birmingham
Comprehensive Cancer Center*

12:15 pm Adjourn

Continuing Medical Education

Joint Sponsorship Statement

Jointly sponsored by Vanderbilt University School of Medicine and the Association of American Cancer Institutes.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vanderbilt University School of Medicine and the Association of American Cancer Institutes. Vanderbilt University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Vanderbilt University School of Medicine designates this live activity for a maximum of *12.5 AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives

After participating in this CME activity, participants should be able to describe and discuss:

- Strategies for how cancer centers can plan for growth and improve capacity in the post healthcare reform area.
 - Approaches for including NCI's programmatic priorities, policies, strategies and goals for the national cancer research enterprise in future planning for the nation's cancer centers.
 - Approaches for including information about screening advantages and disadvantages in management plans for patients at risk for breast or prostate cancer.
 - Strategies for overcoming clinical and financial barriers to including companion diagnostics in treatment decisions at cancer centers.
 - Strategies for providing information to providers and patients about the impact of obesity, poor diet, and lack of physical activity as risk factors in cancers of the breast, endometrium, colon, kidney, and esophagus.
 - Approaches to providing outreach education regarding cancer prevention, early detection, and cancer care to underserved populations.
-

Americans with Disabilities Act

It is the policy of Vanderbilt School of Medicine not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact Sara Arvey at 412-605-1476 or attach a note to your registration form.

Faculty Disclosure

It is the policy of Vanderbilt University School of Medicine and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience

This trans-disciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects.

Leaders of AACI's 95 academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical leaders—leaders from industry and government agencies as well as those of cancer research and advocacy organizations attend the meeting. All attendees have a significant impact on cancer research and patient care in the U.S. Meeting attendees include medical professionals from across the country, such as oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, social workers, psychologists, cancer communication specialists, public health leaders, and other faculty members who focus on cancer.

Disclosure of Financial Relationships

All course directors, planners, and speakers have no financial relationships to disclose with the exception of the following:

Dr. Steven D. Averbuch	Bristol-Myers Squibb	Employee
Dr. William J. Catalona	Beckman Coulter Ohmx Nanosphere	Consultant/Research Grant/Speaker Fee Consultant/Research Grant Consultant
Dr. Stephen Gruber	Myriad Genetics	Consultant
Dr. Caryn Lerman	Pfizer	Research Grant
Dr. Ian McCaffery	Genentech/Roche Amgen, Inc	Shareholder/Employee Shareholder

Speakers

David S. Alberts, MD

**Director
University of Arizona Cancer Center**

Dr. Alberts has had a strong career focus on translational cancer prevention and treatment research. The emphasis of his laboratory-based and clinical research has been on the chemoprevention and treatment of such pervasive and potentially deadly diseases as cancers of the breast, colon, ovary, and skin. Clinically, Dr. Alberts pioneered new treatments for advanced ovarian cancers, including in vitro tumor cell chemosensitivity testing for personalized medicine strategies, intraperitoneal chemotherapy, and maintenance chemotherapy.

Presently, Dr. Alberts helps to coordinate Phase I and II and pharmacokinetic drug studies at the Arizona Cancer Center for molecularly-targeted chemopreventive agents and anticancer drugs. His laboratory research is concentrated on the evaluation of new early detection and response surrogate endpoint biomarkers for cancer prevention trials with a special focus on precursor lesions for bladder, breast, colon, cervical, endometrial, ovarian, prostate, and skin cancers, using quantitative histopathology (i.e., karyometric) approaches.

Dr. Alberts has authored or co-authored over 499 peer reviewed publications, more than 100 book chapters and 60 invited articles, and has served as Editor and Co-Editor of six books (e.g. *Fundamentals of Cancer Prevention, Second Edition*, Springer Verlag, 2009 and *Intraperitoneal Therapy for Ovarian Cancer*, Springer Verlag, 2010). He joined the University of Arizona College of Medicine in 1975 as an assistant professor, where he has served for over 35 years. Dr. Alberts is currently Regents Professor of Medicine, Pharmacology, Nutritional Science, and Public Health at the University of Arizona College of Medicine, and director of the Arizona Cancer Center.

Frederick R. Appelbaum, MD

**Director, Clinical Research Division
Fred Hutchinson Cancer Research Center**

Dr. Appelbaum is director of the Clinical Research Division, Fred Hutchinson Cancer Research Center, head of Oncology, University of Washington School of Medicine, and president and executive director of the Seattle Cancer Care Alliance. He is a diplomat on the American Boards of Internal Medicine and Medical Oncology, and is past chair of the Board of Scientific Advisors of the National Cancer Institute. Additionally, he has been a board member of a number of scientific societies, including the American Society of Hematology, American Society of Clinical Oncology, the American Society for Blood and Marrow Transplantation and is Chair of the Leukemia Committee of the Southwest Oncology Group.

Dr. Appelbaum is head of the Clinical Transplant Research Program in the FHCRC/ University of Washington Cancer Consortium and principal investigator on several National Institutes of Health grants. He is the author of over 900 scientific articles and was the lead author on the first paper to describe the successful use of autologous marrow transplantation. Dr. Appelbaum's current areas of research interests center on the biology and treatment of hematologic malignancies.

Steven D. Averbuch, MD

**Vice President, Early Global Clinical Research Oncology
Head, Pharmacodiagnosics
Bristol-Myers Squibb Company**

Dr. Averbuch is currently vice president, Early Global Clinical Research Oncology and head, Pharmacodiagnosics, Bristol-Myers Squibb (BMS) Company based in Lawrenceville, New Jersey. Since joining BMS, Dr. Averbuch has led the strategic direction for the exploratory oncology pipeline through the execution of Phase 2. He is responsible for the clinical research contributions to business development and he has participated in seven successful transactions. In 2008, Dr. Averbuch founded and established the Pharmacodiagnostic Team, the precursor to the Pharmacodiagnostic Center of Excellence (CPDx) of which he is the current head. The CPDx is a multidisciplinary team of subject matter experts responsible for the development and commercialization of companion diagnostics for BMS products across all therapeutic areas.

Currently, Dr. Averbuch is responsible for leading an organizational change management initiative to enable translational research and development across R&D. He previously held positions at Merck Research Laboratories, AstraZeneca, and Mount Sinai School of Medicine. Dr. Averbuch received his MD and internal medicine training from the University of Illinois, Chicago and his medical oncology training at the National Cancer Institute.

Dr. Averbuch has authored over 60 peer reviewed publications and book chapters and he is a co-author on one patent. He is currently on the advisory board for the University of Kansas Institute for Advancing Medical Innovation. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research having served on multiple committees for both organizations.

Speakers

Alan Balch, PhD

**Vice President, Preventive Health Partnership
American Cancer Society, Inc
American Diabetes Association
American Heart Association**

Dr. Balch works for the American Cancer Society, the American Diabetes Association, and the American Heart Association as the vice president of the Preventive Health Partnership. The goal of this joint initiative is to encourage the prevention and early detection of cancer, diabetes, heart disease and stroke by increasing public awareness about healthy lifestyles, increasing the focus on prevention among healthcare providers, and supporting public policy to increase funding for and access to prevention programs and research.

Previous to this position, Dr. Balch was the executive director of Friends of Cancer Research — a Washington D.C.-based non-profit that works with members of the medical, scientific, and advocacy community to identify and overcome barriers to the advancement of cancer research. He volunteers as a member of the board of directors for the Patient Advocate Foundation, Fight Colorectal Cancer, and the Center for a New American Dream.

Pamela Protzel Berman, PhD, MPH

**Deputy Director
Division of Cancer Prevention and Control
Centers for Disease Control and Prevention**

Dr. Protzel Berman is the deputy director of the Centers for Disease Control and Prevention's (CDC) Division of Cancer Prevention and Control. Her focus is on the development of emerging initiatives, providing operational and management leadership and setting strategic direction for the Division. Dr. Protzel Berman has been with CDC since 1991 and received her PhD in Health Services Research and Health Policy at the Rollins School of Public Health, Emory University. Dr. Protzel Berman's research focused on economic and political factors affecting funding for state cancer control programs. Previously, she served as associate director and deputy associate director for policy, planning, and evaluation in CDC's National Center for Injury Prevention and Control and National Immunization Program, respectively. She has had substantial congressional experience in both the U.S. House of Representatives and Senate and has worked in government relations for a public health organization.

Otis Webb Brawley, MD, FACP

**Chief Medical & Scientific Officer
American Cancer Society**

As the chief medical and scientific officer and executive vice president of the American Cancer Society, Dr. Brawley is responsible for promoting the goals of cancer prevention, early detection, and quality treatment through cancer research and education. He champions efforts to decrease smoking, improve diet, detect cancer at the earliest stage, and provide the critical support cancer patients need. He also guides efforts to enhance and focus the research program, upgrade the Society's advocacy capacity, and concentrate community cancer control efforts in areas where they will be most effective. Further, as an acknowledged global leader in the field of health disparities research, Dr. Brawley oversees the Society's work to eliminate disparities in access to quality cancer care.

Dr. Brawley currently serves as professor of hematology, oncology, medicine and epidemiology at Emory University. He is also a medical consultant to the Cable News Network (CNN). From April 2001 to November 2007 he was medical director of the Georgia Cancer Center for Excellence at Grady Memorial Hospital in Atlanta, and deputy director for cancer control at the Winship Cancer Institute at Emory University. He has also served as a member of the Society's Prostate Cancer Committee, co-chaired the U.S. Surgeon General's Task Force on Cancer Health Disparities, and filled a variety of positions at the National Cancer Institute (NCI).

Currently, Dr. Brawley is a member of the Centers for Disease Control and Prevention (CDC) Advisory Committee on Breast Cancer in Young Women. He was a member of the CDC Breast and Cervical Cancer Early Detection and Control Advisory Committee. He served as a member of the Food and Drug Administration Oncologic Drug Advisory Committee and chaired the NIH Consensus Panel on the Treatment of Sickle Cell Disease.

William J. Catalona, MD

**Director, Clinical Prostate Cancer Program
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University**

Dr. Catalona is professor of urology and director of the Clinical Prostate Cancer Program at Northwestern University Feinberg School of Medicine. He was the first to show that PSA could be used as a screening test for prostate cancer. His awards include the Gold Cystoscope, 1986; Hugh Hampton Young Award, 1994; Eugene Fuller Triennial Prostate Medal, 1998; The Johns Hopkins Society of Scholars, 1994; Barringer Medal, 1999; Edward L. Keyes Medal, 2003; Charles Huggins Medal,

Speakers

2005; New York Academy of Medicine's Ferdinand Valentine Medal, 2007, and the Ramon Guiteras Lectureship, 2011. He has performed 6,000 nerve-sparing radical prostatectomies and authored more than 430 articles and books. His research interests are prostate cancer screening, treatment, and genetics. He has been principal investigator on grants from NIH, Department of Defense, American Cancer Society and Prostate Cancer Foundation.

William S. Dalton, PhD, MD

**Director, Personalized Medicine Institute
Moffitt Cancer Center
CEO, M2Gen**

Dr. Dalton's basic and translational research interests focus on molecular mechanisms of drug resistance and new drug discovery. Dr. Dalton and his colleagues have examined the influence of the tumor microenvironment on drug response and proposed that environmentally mediated drug resistance protects tumor cells from stress and cell death by two mechanisms: 1) a paracrine mechanism due to soluble cytokine factors produced as a result of the tumor cell environment interaction; and 2) a physical contact mechanism they have termed "cell adhesion" mediated drug resistance.

Dr. Dalton is also interested in the development of personalized cancer care and patient-centered outcomes research. His interests include studying the informatics needs and challenges in cancer research and care, and the development of information systems to meet those needs. Dr. Dalton serves as president of AACI and is the former CEO of the Moffitt Cancer Center.

Yu Ding, PhD

**Post Doctoral Associate, Paddison Lab
Fred Hutchinson Cancer Research Center**

Dr. Ding is a postdoctoral fellow in Dr. Patrick Paddison's lab at Fred Hutchinson Cancer Research Center. He received his PhD at Shanghai Institutes for Biological Sciences studying Wnt signaling pathway, a well-known pathway that is related to several types of cancer. After graduation, he joined Dr. Paddison's lab for brain tumor research. As the recipient of first AACI Translational Cancer Research Fellowship, his work focuses on Glioblastoma multiforme (GBM). Using GBM samples derived from patients, he is evaluating different methods for identifying which genes are differentially required for GBM survival.

H. Shelton Earp III, MD

**Director
UNC Lineberger Comprehensive Cancer Center**

Dr. Earp is the Lineberger Professor of Cancer Research and a professor in the Departments of Medicine and Pharmacology. In his role as director at the UNC Lineberger Comprehensive Cancer Center, he supports basic, clinical and public health cancer research and care at one of the country's premier public universities and academic medical centers. He serves as principal investigator of the UNC Breast Cancer SPORE and UNC Lineberger Comprehensive Cancer Center grants. Dr. Earp's laboratory conducts translational breast and prostate cancer and childhood leukemia research as well as basic research on the regulation of cancer cell growth, differentiation and death. He has authored over 145 biomedical-research papers. Dr. Earp has received UNC School of Medicine teaching awards and chaired national review committees for the American Cancer Society and the National Cancer Institute. He has served as president of AACI, on the NCI Board of Scientific Advisors, and on the advisory boards of ten cancer centers. His lab is supported by two NIH R01 grants and funding from the Breast Cancer Research Foundation.

Shirley Gray, MA

**Associate Director of Administration
The Winthrop P. Rockefeller Cancer Institute**

Ms. Gray is the director of administration for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS). She has served in this capacity for 10 years and previously directed the patient and professional education programs for the cancer institute. With a master's degree in writing and her extensive experience as a grant writer, she also holds an appointment as an instructor in the UAMS Graduate School where she teaches a scientific writing class.

Stephen B. Gruber, MD, PhD, MPH

**Director
USC Norris Comprehensive Cancer Center**

Dr. Gruber is a board-certified medical oncologist and cancer geneticist who serves as director of the USC Norris Comprehensive Cancer Center. After graduating from the University of Pennsylvania in 1984, Dr. Gruber earned his PhD in cancer epidemiology from Yale University and his MD from the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania and his fellowship in medical oncology and post-doctoral research fellowship at Johns Hopkins working in the research groups led by Gloria Petersen, PhD, and Bert Vogelstein, MD. After joining the faculty at the University of

Speakers

Michigan in the Division of Molecular Medicine and Genetics, Dr. Gruber completed a fellowship in clinical medical genetics. He has been a continuously funded investigator from NIH since 1998, and his research in molecular epidemiology has concentrated on genetic susceptibility to cancer and strategies to reduce the burden of cancer in families with Mendelian cancer syndromes and in populations at risk.

Carmen E. Guerra, MD, MSCE, FACP

**Associate Professor of Medicine, Associate Chief of Staff
Abramson Cancer Center
University of Pennsylvania**

Dr. Guerra is an associate professor of medicine and associate chief of staff of the Abramson Cancer Center of the Perelman School of Medicine of the University of Pennsylvania. At Penn, she is also an associate scholar of the Center for Clinical Epidemiology and Biostatistics and a senior scholar at the Leonard Davis Institute of Health Economics. Dr. Guerra completed her MD at the University of Rochester School of Medicine and Dentistry, her internship and residency in internal medicine at the Strong Memorial Hospital and a MS in clinical epidemiology at the University of Pennsylvania. Dr. Guerra is a board-certified internist and a fellow of the American College of Physicians.

Dr. Guerra is also a cancer control researcher and the recipient of several NIH and American Cancer Society grants that have supported her research to better understand and overcome barriers to cancer screening. She is also the recipient of the Amos Medical Faculty Development Program fellowship from the Robert Wood Johnson Foundation. Dr. Guerra is a member of the board of directors of the American Cancer Society, East Central Division and serves on the medical advisory board for the Susan G. Komen for the Cure Philadelphia.

At the Abramson Cancer Center, Dr. Guerra established and currently directs two programs focused on the vulnerable populations of Philadelphia: a colorectal cancer screening navigation program and the Healthy Woman Program.

Lauren E. Hackett, MPA

**Executive Director for Administration
Vanderbilt-Ingram Cancer Center**

Ms. Hackett joined the Vanderbilt-Ingram Cancer Center in September 2011. As executive director for administration, she plays a critical and integrative leadership role administering the clinical and research enterprises and sustaining the mission of the Center. She has nearly 20 years of experience in administration, most recently at the New York University Cancer Institute, where she served as executive director for administration since 2004. She held similar roles with the Yale School of Medicine and Yale Cancer Center. Ms. Hackett serves as the administrative representative

for Vanderbilt-Ingram on the National Comprehensive Cancer Network Board of Directors, has or currently serves on review panels and program committees for the AACI/CCAF, sits on advisory boards of several other NCI Cancer Centers, and has participated in over 13 NCI site visits. Ms. Hackett, who earned a bachelor's degree in psychology from the University of Massachusetts Amherst, has a Masters of Public Administration from the University of New Haven.

Janie K. Hofacker, RN, MS

**Director of Programs
Association of American Cancer Institutes**

Ms. Hofacker oversees the implementation and operations of the AACI Clinical Research Initiative and directs its programmatic and strategic expansion. She is also responsible for developing and implementing new initiatives that will provide value to AACI's membership.

Ms. Hofacker joined AACI after two years as administrative director of the Clinical Trials Office at The Ohio State University Comprehensive Cancer Center. She began her clinical research experience as a clinical research coordinator (1992-1998), regulatory manager (1998-2003) and clinical research manager (2003-2008) at the University of Pittsburgh Cancer Institute.

Caryn Lerman, PhD

**Deputy Director
Abramson Cancer Center
University of Pennsylvania**

Dr. Lerman is the Mary W. Calkins Professor in the Department of Psychiatry and deputy director of the Abramson Cancer Center at the University of Pennsylvania. She also directs the Center for Interdisciplinary Research on Nicotine Addiction. Her research focuses on understanding the genetic and neural substrates of nicotine addiction and the application of this knowledge to drug development and delivery. Dr. Lerman is an elected member of the Institute of Medicine, and a former member of the National Cancer Institute's Board of Scientific Advisors and the National Human Genome Research Institute Advisory Council. She is currently a member of the National Advisory Council for the National Institute on Drug Abuse.

Mia A. Levy, MD, PhD

**Director, Cancer Clinical Informatics
Vanderbilt-Ingram Cancer Center**

Dr. Levy is the director of Cancer Clinical Informatics for the Vanderbilt-Ingram Cancer Center and an assistant professor of Biomedical Informatics and Medicine.

Speakers

Dr. Levy received her undergraduate degree in bioengineering from The University of Pennsylvania in 1997 and her MD from Rush University in 2003. She then spent six years at Stanford University completing post-graduate training in internal medicine and medical oncology while completing her PhD in biomedical informatics. She joined the faculty at Vanderbilt as an assistant professor in biomedical informatics and medicine in 2009. She is a practicing medical oncologist specializing in the treatment of breast cancer.

Dr. Levy's research interests include biomedical informatics methods to support the continuum of cancer care and cancer research. Current research projects include informatics methods for 1) image based cancer treatment response assessment using quantitative imaging, 2) clinical decision support for treatment prioritization of molecular subtypes of cancer, 3) protocol based plan management and 4) learning cancer systems.

Marcy A. List, PhD

**Associate Director of Administration
University of Chicago Comprehensive Cancer Center**

Dr. List is the associate director for administration at the University of Chicago Comprehensive Cancer Center (UCCCC), responsible for operations, finance, administration, and various clinical research and translational initiatives across the UCCCC's six scientific programs. In addition, she is responsible for scientific oversight of the UCCCC's Cancer Clinical Trials Office, which manages the regulatory affairs for all adult cancer-related clinical trials and sets policies and procedures for the conduct of all cancer-related trials at the institution, including pediatrics. Prior to assuming her current administrative role, Dr. List was an active cancer control investigator who served on a number of National Cancer NCI peer review committees, the Cancer Control and Health Outcomes Committee of CALGB (1999-2005) and Health Outcomes Committee of RTOG (2001-2009). Her own research focused on quality of life in head and neck cancer patients, for which she is nationally recognized as a leader in the field, having participated as a project leader in an NCI-funded program project grant on rehabilitation in head and neck cancers for over a decade. Dr. List is currently a member of the Cancer Center Administrators Forum, and served on the program committee for the 2004 fall meeting.

Douglas R. Lowy, MD

**Deputy Director
National Cancer Institute**

Dr. Lowy is deputy director of the National Cancer Institute (NCI), National Institutes of Health, and chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at NCI. He received his MD from New York University School of Medicine and trained in internal medicine at Stanford University and dermatology at Yale.

Dr. Lowy's research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth. The papillomavirus research is carried out in close collaboration with John T. Schiller, PhD, with whom he has co-authored more than 100 papers over the past 25 years. In the 1980s they studied the genetic organization of papillomaviruses and identified the oncogenes encoded by the virus. More recently, they have worked on papillomavirus vaccines and the papillomavirus life cycle. Their laboratory was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the two FDA-approved HPV vaccines.

Dr. Lowy's growth regulation research includes prior studies that established the importance of the ras gene family in cancer and the main mechanisms by which the NF1 tumor suppressor gene regulates normal cell growth. His growth regulation research is now focused primarily on the DLC family of tumor suppressor genes and their mechanism of action. Dr. Lowy is a member of the National Academy of Sciences (NAS) and also a member of the Institute of Medicine of the NAS. For his pioneering work he and Dr. Schiller have received numerous honors including the 2011 Albert B. Sabin Gold Medal Award.

Ian McCaffery, PhD

**Associate Director, Oncology Biomarker Development
Genentech, Inc.**

Dr. McCaffery received his PhD from the University of Leeds in the United Kingdom and gained postdoctoral experience at the University of Virginia investigating mechanisms of gene regulation. He has over 12 years of experience in the biotechnology industry leading target and biomarker discovery and development programs in clinical development. Most recently, Dr. McCaffery spent eight years in the Medical Sciences Department at Amgen where he directed the oncology therapeutic area biomarker portfolio. Currently, Dr. McCaffery heads the companion diagnostics group at Genentech, developing and validating predictive tests to inform and enable targeted clinical development programs in oncology, immunology and infectious disease areas.

Mark B. McClellan, MD, PhD

**Director
Engelberg Center for Health Care Reform
The Brookings Institution**

Dr. McClellan is senior fellow, director of the Engelberg Center for Health Care Reform, and Leonard D. Schaeffer Chair in Health Policy Studies at the Brookings Institution, where his work focuses on providing practical solutions to achieve high-quality, innovative, affordable health care with particular emphasis on identifying opportunities on the national, state, and local levels.

Speakers

A physician and economist by training, Dr. McClellan also serves as an advisor to the Bipartisan Policy Center's Leaders' Project on the State of American Health Care; as co-chair for the Robert Wood Johnson Foundation's Commission to Build a Healthier America; and as chair of the Food and Drug Administration's (FDA) Reagan-Udall Foundation.

Previously, Dr. McClellan served as the administrator for the Centers for Medicare and Medicaid Services (CMS) from 2004-2006 and as commissioner of the FDA from 2002-2004. While at CMS and FDA, Dr. McClellan developed and implemented major reforms in health policy, including the Medicare prescription drug benefit, the FDA's Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care.

Beverly S. Mitchell, MD

George E. Becker Professor of Medicine
Director
Stanford Cancer Institute

Dr. Mitchell is the George E. Becker Professor of Medicine and director of the Stanford Cancer Institute. Before joining the Stanford faculty in 2005 she led the Molecular Therapeutics Program at Lineberger Comprehensive Cancer Center at the University of North Carolina (UNC), Chapel Hill, where she also served as associate director for translational research and chief of the Division of Hematology/Oncology. Dr. Mitchell's research relates to the development of new therapies for hematologic malignancies. She is interested in preclinical proof-of-principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid metabolism in malignant cells. Dr. Mitchell is also interested in the translation of these studies into clinical trials. She has authored more than 130 peer-reviewed articles. She is a member of the Institute of Medicine of the National Academies of Sciences.

Dr. Mitchell has served as president of the American Society of Hematology and as the chair of the Medical and Scientific Affairs Committee of the Leukemia and Lymphoma Society. She was a faculty member in the Departments of Medicine and Pharmacology at the University of Michigan for 16 years before moving to UNC.

Alfred I. Neugut, MD, PhD

Associate Director for Population Sciences
Herbert Irving Comprehensive Cancer Center
Columbia University

Dr. Neugut is the Myron M. Studner Professor of Cancer Research and professor of medicine and epidemiology at Columbia University, associate director of the Herbert Irving Comprehensive Cancer Center at Columbia, and co-director of the Cancer Prevention Center of New York Presbyterian Hospital. He is a medical oncologist

whose research focuses on cancer epidemiology and prevention, as well as health outcomes research.

Dr. Neugut's research has centered on cancer epidemiology and prevention, including important studies focused on risk factors for the occurrence of colorectal adenomatous polyps. These studies extended the use of colonoscopy and fecal occult blood testing for routine screening and diagnosis. An editorial by Dr. Neugut in 1988 was the first to suggest the use of colonoscopy for routine screening of asymptomatic adults, a common practice now.

His current research focuses on the quality of treatment received by cancer patients, including racial and other disparities in receipt of care and resultant outcomes. He has ongoing projects on quality of palliative care in prostate cancer as well as medication adherence in breast and colon cancer. He also is principal investigator of a training program aimed at increasing the number of investigators on HIV and cancer in South Africa.

Edward E. Partridge, MD

Director
University of Alabama at Birmingham Comprehensive Cancer Center

Dr. Partridge is director of the UAB Comprehensive Cancer Center, professor of obstetrics and gynecology, former director of the Division of Gynecologic Oncology and holds the Evalina B. Spencer Endowed Chair in Oncology. His clinical interests are cancer control and prevention; cervical cancer; community based participatory research; gynecologic oncology; and minority health disparities.

He is principal investigator (PI) of the National Cancer Institute's Deep South Network for Cancer Control which utilized community health advisors to improve the cancer health status of the African-American population in the rural south and the Morehouse School of Medicine/Tuskegee University/UAB Cancer Center Partnership to enhance the research capability of the minority-serving institutions and the ability of the cancer center to conduct cancer disparity research. He is also PI of the UAB component of the Cervical Cancer SPORE at Johns Hopkins. He is PI of the UAB Cancer Navigation Network, a CMS-funded innovation project utilizing lay navigators across the continuum of cancer care.

Dr. Partridge recently served as president of the national board of the American Cancer Society. He was chairman of the Commission on Cancer for the American College of Surgeons and currently serves as chairman of the Cervical Cancer Screening Guidelines Committee of the National Comprehensive Cancer Network. He is on the board of directors of the Mid-South Division of the American Cancer Society having served as chairman of that board. He has served on the national board of directors of the American Cancer Society for the past twenty years.

Speakers

Dorothy E. Puhly, MBA

**Executive Vice President and Chief Operating Officer
Dana-Farber Cancer Institute**

Ms. Puhly is executive vice president and chief operating officer for the Dana-Farber Cancer Institute. Previously, she served as its chief financial officer and assistant treasurer. Prior to Dana-Farber, Ms. Puhly was the CFO for New England Medical Center Hospitals. She has also served as a healthcare consultant for the public accounting firm of Ernst & Young and as director of the Hospital Bureau for the Massachusetts Rate Setting Commission.

Ms. Puhly is chair of the board and executive committees of MASCO (Medical Academic and Scientific Community Organization, Inc.) and is a director and chair of the financial committee at CRICO (Controlled Risk Insurance Company). In addition, Ms. Puhly is a lecturer in health management at the Harvard School of Public Health.

Tony Reid, PhD, MD

**Academic Director, Clinical Trials Office
Associate Professor, Medicine
Moore's UCSD Cancer Center**

Dr. Reid is the chair of AACI's Clinical Research Initiative. He is the director of the Clinical Trials Office at UCSD, a position he has held since 2007.

He received his medical degree from Stanford University, where he also received a PhD in biochemistry. Dr. Reid's PhD thesis focused on the use of interferon to treat cancer and identified pathways involved in the anticancer effects of interferon. These studies led to the recognition that many malignancies lacked pathways that block viral infections. These observations have formed the basis for subsequent research work and clinical trials exploiting the defects in antiviral pathways in tumors to treat tumors with gene therapy vectors.

He was the lead investigator on the original trials using Onyx-015 to treat colorectal cancer and has pioneered the use of adenoviral and vaccinia vectors for the treatment of cancer. Dr. Reid has been at the forefront of using interventional radiology to selectively deliver therapeutic directly to the tumor using the tumor's own vascular supply.

Dr. Reid has received national recognition for his work including the awards from the Interferon Society, the International Society of Gene Therapy and the Society for Interventional Radiology. Dr. Reid is on the review board of numerous prestigious journals including Nature Cancer Gene Therapy, Gene Therapy and Clinical Cancer Research.

Thomas A. Sellers, PhD, MPH

**Director
Moffitt Cancer Center**

Dr. Sellers completed post doctoral training in statistical genetics at Louisiana State University in 1989. He then joined the faculty of the University of Minnesota School of Public Health where he attained the rank of tenured associate professor and served as program leader and associate director of their cancer center. In 1998 he joined the Mayo Clinic Cancer Center as professor of epidemiology and associate director of population sciences and in 2002 he became deputy director.

Dr. Sellers joined the Moffitt Cancer Center in August 2003 as executive vice president and associate center director for cancer prevention and control. He was appointed director of the Moffitt Research Institute in 2006 and cancer center director in July 2012.

The pathophysiology of cancer reflects the interaction of genetic and environmental factors. Dr. Sellers has been using the tools of epidemiology and molecular genetics to sort out this complex interplay as a means to inform better methods for prevention and clinical management. He is the author of more than 260 peer-reviewed publications and has garnered more than \$45 million in grant support as principal or co-principal investigator from the National Cancer Institute (NCI). Service activities include external advisory boards for 15 cancer centers, member of NCI's Board of Scientific Counselors, and most recently as a member of the board of directors of the American Association for Cancer Research.

Margaret R. Spitz, MD, MPH

**Professor
Baylor College of Medicine
Dan L. Duncan Cancer Center**

Dr. Spitz joined the faculty of MD Anderson Cancer Center in 1981 and was named founding chair of the Department of Epidemiology in 1995, until stepping down in 2008. During her 27-year career at M. D. Anderson, Dr. Spitz conducted innovative molecular and genetic epidemiology research that helped propel their Cancer Prevention program into international prominence. Dr. Spitz recruited an outstanding cadre of epidemiologists to her department, and at her retirement, the department included 29 faculty members with more than 215 employees and a research budget of over \$20 million. A National Cancer Institute (NCI) peer review concluded that this epidemiology program was "without peer". She joined Baylor College of Medicine in 2009 to provide strategic direction in growing their population sciences program.

Speakers

Dr. Spitz has a long standing interest in genetic susceptibility to lung cancer and has contributed to more than 400 scientific publications, with a research focus on the study of interindividual variation in susceptibility to tobacco carcinogenesis. She has developed a lung cancer risk prediction model, has participated in lung cancer genome-wide association studies and is a founding member of the International Lung Cancer Consortium. She advanced the concept of Integrative Epidemiology that links classical epidemiology with the emerging wealth of genomic, epigenomic and transcriptomic information for prediction of cancer risk and outcome.

Nationally, Dr. Spitz served as co-chair of NCI's Lung Cancer Progress Review Group and on the board of scientific advisors to NCI. She sits on the external scientific advisory committees of several major cancer centers. She has served as a strategic advisor to the NCI's intramural Division of Cancer Epidemiology and Genetics and is past president of the American Society of Preventive Oncology. She was a member of the board of advisors of the American Association for Cancer Research.

Dr. Spitz received her MD from the University of Witwatersrand Medical School in Johannesburg, South Africa, and earned her MPH from The University of Texas School of Public Health.

Brian C. Springer, MHA

**Executive Vice President
Roswell Park Cancer Institute**

Mr. Springer was appointed executive vice president for Roswell Park Cancer Institute (RPCI) in 2011. He works closely with Donald L. Trump, MD, RPCI president and CEO, and Candace S. Johnson, PhD, RPCI deputy director, to oversee the development, direction and operation of the Institute, including administrative, scientific and clinical departments, all mission-area programs, oversight of strategic planning initiatives and the renewal of the National Cancer Institute core grant. He also works closely with senior faculty and staff to integrate administrative and departmental functions.

Mr. Springer has held senior administrative leadership positions at two nationally designated comprehensive cancer centers. At the Alvin J. Siteman Cancer Center, St. Louis, Missouri, he served as Executive Director and was responsible for finance and operations. During his time at the Comprehensive Cancer Center of Wake Forest University (CCCWFU), Winston-Salem, North Carolina, Mr. Springer served as assistant director of finance and administration. Prior to this role, he served as director of clinical research management at CCCWFU.

Mr. Springer serves on the executive committee of the Cancer Center Administrators' Forum, and is a member of the National Comprehensive Cancer Network.

Barbara Duffy Stewart, MPH

**Executive Director
Association of American Cancer Institutes**

Since 1999, Ms. Stewart has served as executive director of the Association of American Cancer Institutes (AACI), comprising 95 of the leading academic and free-standing cancer research centers in the United States. Ms. Stewart oversees all administrative, financial and external affairs of the Association, and conceives and implements programs and strategies that benefit the nation's cancer centers and contribute to the goals of the national cancer program.

Before joining AACI, Ms. Stewart was director of communications and public affairs at the University of Pittsburgh Cancer Institute (UPCI). She was responsible for UPCI's interactions with business, community, and government leaders to increase awareness of UPCI's novel cancer programs and activities.

Ms. Stewart is president of the board of directors of the National Coalition for Cancer Research, Washington, DC, serves on the executive committee of Friends of Cancer Research, Washington, DC, and is a member of the Metro board of directors of the YMCA, Pittsburgh. She holds a Master of Public Health degree from the University of Pittsburgh and a Bachelor of Arts degree in government from Georgetown University.

Dan Theodorescu, MD, PhD

**Director
University of Colorado Cancer Center**

Dr. Theodorescu is the Paul Bunn Professor and director of the NCI-designated Comprehensive Cancer Center at the University of Colorado. He is also professor of surgery and pharmacology and attending urologic oncologist. He received his urological training in the Surgical Scientist Program at the University of Toronto where he also obtained a PhD in molecular and cell biology with Robert Kerbel, PhD, an internationally known cancer biologist. He then completed a clinical fellowship in urologic oncology at the Memorial Sloan Kettering Cancer Center in New York City. Currently, Dr. Theodorescu has a clinical practice in urologic oncology with a special interest in bladder cancer and minimally invasive robotic surgery, and he is a practicing surgeon who has made seminal contributions to the clinical practice of urology through his contributions to prostate brachytherapy and the development of a new modification of the Hautmann orthotopic bladder replacement.

Dr. Theodorescu is an international leader in translational cancer research focused on identifying the molecular mechanisms leading to bladder and prostate cancer metastasis and their potential applications to patients with these diseases.

Speakers

Dr. Theodorescu has three significant accomplishments to date: The identification of a new metastasis suppressor gene, RhoGDI2, in human cancer; the development of COXEN (CO-eXpression Extrapolation) a radical new strategy aimed at personalizing cancer therapy and identifying which new drugs have a high likelihood of being effective in patients based solely on in vitro assays; and deep sequencing and gene expression and mass spectrometry based proteomics work that has resulted in the discovery of novel tissue and urinary biomarkers of bladder and prostate cancer.

Dr. Theodorescu's laboratory is currently funded by grants from the National Institutes of Health (NIH) and he is both a project leader and has been the program leader of an NIH program project in prostate cancer signal transduction.

Patricia A. Thompson, PhD

**Associate Professor, Cellular and Molecular Medicine
University of Arizona Cancer Center**

Dr. Thompson is an associate professor in the Department of Cellular and Molecular Medicine and program leader of the Cancer Prevention and Control Program at the Arizona Cancer Center and member of the Cancer Biology Graduate Interdisciplinary Program. Her research focuses on the prevention of colorectal and breast cancer with specific interest in targeting the role of inflammation and inflammatory triggers in the carcinogenesis process. Her interest in obesity relates to the effects of excess energy intake on metabolism that lead to a breakdown in systemic and tissue level homeostasis.

Dr. Thompson's laboratory works on hypotheses relating local and systemic inflammation, accelerated aging, and alterations in the gut flora to tumor initiation, promotion and progression. She is working under the primary hypothesis that metabolic disturbances that occur at a higher incidence with obesity are the equivalent of an accelerated aging process that acts as a major trigger of systemic disturbances that promote tumorigenesis.

Linda K. Weiss, PhD

**Director, Office of Cancer Centers
National Cancer Institute**

Dr. Weiss is director of the Office of Cancer Centers of the National Cancer Institute. Prior to joining NCI in 2000 as a program director in the Organ Systems Branch, Dr. Weiss was director and principal investigator of the SEER Program and co-director of the Epidemiology Program at the Karmanos Cancer Institute at Wayne State University. In these roles, she held responsibility for ensuring compliance with contractual program and budget requirements of NCI, state cancer reporting requirements, and privacy and confidentiality regulations; liaison activities with local

hospitals, physicians, and scientists; and facilitation of research through the SEER Registry with investigators from multiple disciplines. Dr. Weiss' research during this time period focused primarily on a long-term epidemiological study of exogenous hormone use and risk of breast cancer.

Walter C. Willett, MD, DrPH

**Professor and Chair, Department of Nutrition
Harvard University**

Dr. Willett is professor of epidemiology and nutrition and chairman of the Department of Nutrition at Harvard School of Public Health and professor of medicine at Harvard Medical School. Dr. Willett has focused much of his work over the last 30 years on the development of methods, using both questionnaire and biochemical approaches, to study the effects of diet on the occurrence of major diseases. He has applied these methods starting in 1980 in the Nurses' Health Studies I and II and the Health Professionals Follow-Up Study. Together, these cohorts that include nearly 300,000 men and women with repeated dietary assessments are providing the most detailed information on the long-term health consequences of food choices.

Dr. Willett has published over 1,500 articles, primarily on lifestyle risk factors for heart disease and cancer, and has written the textbook, *Nutritional Epidemiology*, published by Oxford University Press. He also has written three books for the general public: *Eat, Drink and Be Healthy: The Harvard Medical School Guide to Healthy Eating*, which has appeared on most major bestseller lists; *Eat, Drink, and Weigh Less*, co-authored with Mollie Katzen; and *The Fertility Diet*, co-authored with Jorge Chavarro and Pat Skerrett. Dr. Willett is the most cited nutritionist internationally, and is among the five most cited persons in all fields of clinical science. He is a member of the Institute of Medicine of the National Academy of Sciences and the recipient of many national and international awards for his research.

Timothy J. Wilt, MD, MPH

**Professor of Medicine and Core Investigator
Minneapolis VA Center for Chronic Disease Outcomes Research
University of Minnesota School of Medicine**

Dr. Wilt is a general internist and health services researcher whose work is at the intersection of health care practice, research and policy. He aims to enhance delivery of high value health care and improve evidence-based medical decision making. His work cuts across health care conditions, disciplines and methods with the goal of reducing harms and unnecessary costs while maintaining benefits of medical test and treatment interventions.

Speakers

Dr. Wilt focuses on health promotion as well as prevention, detection and treatment of chronic diseases in older adults commonly managed by primary care providers (especially cancer and urological conditions). He conducts clinical trials, database studies and systematic reviews and meta-analyses of existing evidence to evaluate the effectiveness and harms of health care interventions.

Dr. Wilt serves on national health care practice and policy committees in order to identify, disseminate and implement research findings and make a widespread positive difference in health care delivery. Dr. Wilt is a current member of the US Preventive Services Task Force, the American College of Physicians Clinical Guideline Committee and the VA Preventive Medicine Field Advisory Committee. He is the coordinating editor of the Cochrane Review Group in Prostate Diseases and Urological Cancers, co-director of the Minnesota AHRQ-Evidence-based Practice Center and the Minneapolis VA Evidence Synthesis Program center. He is the chairman of the VA/NCI/AHRQ funded Prostate Cancer Intervention Versus Observation Trial that compared surgery to observation for men with early stage prostate cancer. He has served as faculty mentor for many clinical investigators and authored over 200 peer reviewed publications.

Awardee Profiles

2012 AACI Distinguished Scientist Award



Margaret R. Spitz, MD, MPH
Baylor College of Medicine
Dan L. Duncan Cancer Center

Dr. Spitz joined the faculty of MD Anderson Cancer Center in 1981 and was named founding chair of the Department of Epidemiology in 1995, until stepping down in 2008. During her 27-year career at MD Anderson, Dr. Spitz conducted innovative molecular and genetic epidemiology research that helped propel their cancer prevention program into international prominence. Dr. Spitz recruited an outstanding cadre of epidemiologists to her department, and at her retirement, the department included 29 faculty members with more than 215 employees and a research budget of over \$20 million. A National Cancer Institute (NCI) peer review concluded that this epidemiology program was “without peer.” She joined Baylor College of Medicine in 2009 to provide strategic direction in growing their population sciences program.

Dr. Spitz has a long standing interest in genetic susceptibility to lung cancer and has contributed to more than 400 scientific publications, with a research focus on the study of interindividual variation in susceptibility to tobacco carcinogenesis. She has developed a lung cancer risk prediction model, has participated in lung cancer genome-wide association studies and is a founding member of the International Lung Cancer Consortium. She advanced the concept of integrative epidemiology that links classical epidemiology with the emerging wealth of genomic, epigenomic and transcriptomic information for prediction of cancer risk and outcome.

Nationally, Dr. Spitz served as co-chair of the NCI's Lung Cancer Progress Review Group and on the board of scientific advisors to the NCI. She sits on the external scientific advisory committees of several major cancer centers. She has served as a strategic advisor to the NCI's intramural Division of Cancer Epidemiology and Genetics and is past president of the American Society of Preventive Oncology. She was a member of the board of advisors of the American Association for Cancer Research.

Awardee Profiles

AACI Special Recognition Award



Alan S. Rabson, MD
National Cancer Institute

The Association of American Cancer Institutes (AACI) recognizes Alan S. Rabson, MD, with an AACI Special Recognition Award marking his more than five decades as a pathologist, cancer researcher, administrator and clinical advisor, as well as his numerous discoveries in virology and authorship of more than 180 scientific journal articles.

Dr. Rabson joined the National Institutes of Health (NIH) in 1955 as a pathology resident and became a staff member of the National Cancer Institute (NCI) Laboratory of Pathology the next year, becoming deputy chief of the laboratory in 1970. In 1975, he was named director of NCI's Division of Cancer Biology, Diagnosis and Centers. He was appointed NCI deputy director in 1995 and also served as acting director.

Dr. Rabson is noted for first demonstrating that latent herpesvirus can reside in the human trigeminal ganglion. He also was a leader in studying the oncogenicity of papova viruses and, together with his wife of over five decades and collaborator, Dr. Ruth L. Kirschstein, demonstrated that human cells could be simultaneously infected by two different DNA viruses, adenovirus-12 and SV-40, with the generation potent transforming hybrid viruses.

As a cancer research administrator, Dr. Rabson has been a consistently strong proponent of the value of basic research for the development of novel treatment and prevention approaches, and was an early advocate for the application of molecular cloning and recombinant DNA techniques to cancer research problems.

Dr. Rabson has received numerous awards and recognition over his career, including the Public Health Service Distinguished Service Medal in 1978, membership in the Institute of Medicine of the National Academy of Sciences in 1987, and the American Society for Hematology Outstanding Service Award in 2001. In 2009, Congress established the Alan S. Rabson Award Fellowship at the NCI in recognition of Dr. Rabson's life-long dedication to helping cancer patients and their families cope with their diagnoses, efforts which were also recently recognized by the creation of the NIH intramural Alan S. Rabson Award for Clinical Care for NIH physicians.

2012 AACI Distinguished Public Service Awards



The Honorable Jerry Moran
United States Senate

The Association of American Cancer Institutes (AACI) recognizes U.S. Senator Jerry Moran (R-KS) with its 2012 Distinguished Public Service Award for his outstanding record of support for biomedical research.

Sen. Moran has exhibited exceptional leadership in promoting cancer research both as a congressman and in his service on the Senate Appropriations Committee, as a member of the Subcommittee on Labor, Health and Human Services. The cancer research community is also grateful for Sen. Moran's recognition of the life-saving work of the National Cancer Institute (NCI) and AACI's member institutions, as reflected in his lead sponsorship last year of a Senate resolution highlighting the nation's commitment to cancer research and commemorating the 40th anniversary of the National Cancer Act. Also last year, Sen. Moran delivered his full support to the University of Kansas Cancer Center's bid for NCI designation—the highest recognition for an academic cancer center. The center received the designation in July.



The Honorable Debbie Wasserman Schultz
United States House of Representatives

The Association of American Cancer Institutes (AACI) recognizes U.S. Representative Debbie Wasserman Schultz (D-FL) with its 2012 Distinguished Public Service Award for her outstanding efforts on behalf of cancer patients and medical research.

In March 2009, after announcing her own battle with breast cancer, Rep. Wasserman Schultz introduced the Education and Awareness Requires Learning Young Act, or EARLY Act (H.R. 1740), a piece of legislation that directs the Centers for Disease Control and Prevention to develop and implement a national education campaign about the threat breast cancer poses to all young women, and the particular heightened risks of certain ethnic, cultural and racial groups. This bill became law as part of the Patient Protection and Affordable Care Act in March 2010.

Support

Acknowledgment of Commercial Support

The sponsors express appreciation to the following companies for their support of this educational activity by providing unrestricted educational grants:

- Amgen
- Astellas
- Pfizer
- Varian Medical Systems Foundation, a donor advised fund of Silicon Valley Community Foundation

Acknowledgment of Programmatic Support

The Association of American Cancer Institutes gratefully acknowledges the following organizations for providing program and activity support:

- Amgen
- Astellas
- Bristol-Myers Squibb
- Celgene
- Elekta
- Forte Research Systems
- Gilead
- Velos
- Virtify

Exhibitors

The sponsors express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

Aegis Compliance & Ethics Center, LLP

Aegis provides expert compliance and ethics consulting services across a broad range of industries including Health Care, Finance, Energy, Manufacturing, Retail, Government, and others. Aegis professionals hold leadership positions in national compliance organizations and have worked as Chief Ethics and Compliance Officers and government attorneys. The company draws on decades of leadership experience to create and implement hands-on solutions tailored to its clients' unique needs. The programs Aegis develops have been heralded by both industry experts and government officials as models for the field. Aegis clients are armed with the knowledge and organizational framework to efficiently and effectively maintain compliance, manage risk and succeed in today's environment of increasing regulatory scrutiny.

Idea Elan

Idea Elan is a leading software provider in core facility management with a rapidly growing worldwide customer base. The company specializes in applications and products that enhance lab and core facility productivity and management across an entire institution. Idea Elan partners with core facility managers and financial administrators to save time, effort, and money and to optimize institutions both functionally and financially. Key Idea Elan modules and features include online core facility scheduling, automatic actual usage tracking, work flow management, sample process management, billing/invoicing, integration with LIMS systems, integration with financial ERP systems, reporting, and project management.

iLab Solutions, LLC

iLab Solutions provides a complete web-based core facility management system designed exclusively for academic research institutions, with a particular focus on cancer centers. The iLab system streamlines the entire core service work flow, from identifying services, placing requests and scheduling equipment through financial approval, recharges, invoicing and reporting. iLab allows cancer centers to reduce invalid billing codes, improve compensation rates, simplify reporting compliance, and save time for both core staff and customers. The system can be integrated directly with major financial systems such as SAP, PeopleSoft, and Lawson to ensure seamless data transfer.

Virtify

Virtify is the leading supplier of solutions for handling clinical trial disclosure information to the government website ClinicalTrials.gov. Its product, CTRR (Clinical Trials Registration & Results) provides key automation and tracking capability that allows clients to have trial registration data pushed from a CTMS tool (Virtify is a partner of Forte Research) or trial results data from SAS/Excel/etc to eliminate much of the manual re-entry required to become compliant and maintain that compliance with FDA laws governing disclosure of trial information to the public. CTRR easily integrates with source data systems and shortens the cycle time to get information published, helping to insure trials are published and no grant monies are lost due to non-compliance.
